Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBM Conditioning and ASCT in Elderly Patients with Multiple Myeloma and B-cell Lymphoma
NCT03352765Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2017
- Primary completion
- Nov 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rituximab, bendamustine and melphalan in multiple myeloma (MM) and B cell lymphoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Dose Limiting Toxicities at 1 year. Started Nov 2017; status: active, not recruiting.
02
Drugs
rituximabbendamustinemelphalan
03
Conditions
multiple myeloma (MM)B cell lymphoma
Beyond the preview
Go deeper on NCT03352765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03352765.